Who is sponsoring NCT06914310?

NCT06914310 is sponsored by Mansoura University.

What condition does NCT06914310 study?

NCT06914310 studies Mild Traumatic Brain Injury, Moderate Traumatic Brain Injury (TBI).

What drugs are being tested in NCT06914310?

Interventions: Memantine, Mannitol.

What is the status of NCT06914310?

NCT06914310 is currently NOT_YET_RECRUITING.

Last reviewed 2025-04-06 · How we verify

Memantine as an Additive Therapy in Patients With Traumatic Brain Injury

NCT06914310 PHASE2, PHASE3 NOT_YET_RECRUITING

Memantine has shown promise in mitigating secondary brain injury in previous studies. One study demonstrated that early memantine administration in moderate TBI patients resulted in lower serum neuron-specific enolase levels and improved Glasgow Coma Scale scores. However, other trials investigating memantine's impact on long-term cognitive function in TBI patients have yielded mixed results. There is a need for well-controlled studies to determine the efficacy of memantine in improving neurological and cognitive outcomes in patients with TBI.

Details

Lead sponsor	Mansoura University
Phase	PHASE2, PHASE3
Status	NOT_YET_RECRUITING
Enrolment	80
Start date	Tue Mar 25 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Sun Nov 30 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Mild Traumatic Brain Injury
Moderate Traumatic Brain Injury (TBI)

Interventions

Memantine
Mannitol

Countries

Egypt